Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 69 citing articles:

A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge
Yfat Yahalom-Ronen, Hadas Tamir, Sharon Melamed, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 215
Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
James D. Chalmers, Megan Crichton, Pieter Goeminne, et al.
European Respiratory Journal (2021) Vol. 57, Iss. 4, pp. 2100048-2100048
Open Access | Times Cited: 201
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
Stephen A. Klassen, Jonathon W. Senefeld, Patrick W. Johnson, et al.
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 5, pp. 1262-1275
Open Access | Times Cited: 148
COVID-19 Antibody Tests: A Valuable Public Health Tool with Limited Relevance to Individuals
Rachel Marceau West, Amanda Kobokovich, Nancy Connell, et al.
Trends in Microbiology (2020) Vol. 29, Iss. 3, pp. 214-223
Open Access | Times Cited: 96
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
Arturo Casadevall, Liise‐anne Pirofski, Michael J. Joyner
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 77
Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina
Diego Ojeda, María Mora Gonzalez Lopez Ledesma, Horacio M. Pallarés, et al.
PLoS Pathogens (2021) Vol. 17, Iss. 1, pp. e1009161-e1009161
Open Access | Times Cited: 71
Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
Arturo Casadevall, Quigly Dragotakes, Patrick W. Johnson, et al.
eLife (2021) Vol. 10
Open Access | Times Cited: 59
Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2023) Vol. 7, Iss. 5, pp. 499-513
Open Access | Times Cited: 28
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 25
Autoimmunity and COVID-19 – The microbiotal connection
Nurit Katz‐Agranov, Gisele Zandman‐Goddard
Autoimmunity Reviews (2021) Vol. 20, Iss. 8, pp. 102865-102865
Open Access | Times Cited: 51
Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis
Vikas Bansal, Kiran S. Mahapure, Ishita Mehra, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 44
Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
Juan G. Ripoll, Noud van Helmond, Jonathon W. Senefeld, et al.
Clinical Microbiology Newsletter (2021) Vol. 43, Iss. 4, pp. 23-32
Open Access | Times Cited: 43
Insights into neutralizing antibody responses in individuals exposed to SARS-CoV-2 in Chile
Carolina Beltrán-Pavez, Sebastián Riquelme-Barrios, Aarón Oyarzún-Arrau, et al.
Science Advances (2021) Vol. 7, Iss. 7
Open Access | Times Cited: 42
IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools
Christina Kober, Sandro Manni, Svenja Wolff, et al.
PLoS ONE (2022) Vol. 17, Iss. 1, pp. e0262162-e0262162
Open Access | Times Cited: 35
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 6
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Ligong Lu, Hui Zhang, Meixiao Zhan, et al.
Science China Life Sciences (2020) Vol. 63, Iss. 12, pp. 1833-1849
Open Access | Times Cited: 39
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
Daniele Focosi, Massimo Franchini, Liise‐anne Pirofski, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1594-1594
Open Access | Times Cited: 39
SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays
Gregory J. Walker, Zin Naing, Alberto Ospina Stella, et al.
Viruses (2021) Vol. 13, Iss. 2, pp. 247-247
Open Access | Times Cited: 35
Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19
Jiewen Fu, Chunli Wei, Jiayue He, et al.
International Journal of Biological Sciences (2021) Vol. 17, Iss. 3, pp. 897-910
Open Access | Times Cited: 33
Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
Yfat Yahalom-Ronen, Noam Erez, Morly Fisher, et al.
Vaccines (2022) Vol. 10, Iss. 2, pp. 291-291
Open Access | Times Cited: 23
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
Gisela Canedo-Marroquín, Farides Saavedra, Catalina A. Andrade, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 36
Convalescent plasma therapy in patients with moderate-to-severe COVID-19: A study from Indonesia for clinical research in low- and middle-income countries
Marliana S. Rejeki, Nana Sarnadi, Retno Wihastuti, et al.
EClinicalMedicine (2021) Vol. 36, pp. 100931-100931
Open Access | Times Cited: 30
A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
‪Yasmin Maor‬‏, Eilat Shinar, Marina Izak, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 964-971
Open Access | Times Cited: 10
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis
Henry T. Peng, Shawn G. Rhind, Andrew Beckett
JMIR Public Health and Surveillance (2021) Vol. 7, Iss. 4, pp. e25500-e25500
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top